T2D incidence increases with age, in part due to a decreased ability of ? cells to respond to proliferative cues as they get older. Our lab identified the FoxM1 transcription factor as a critical regulator of ?-cell replication and survival. Foxm1 expression in islets declines with age in mice and humans, but activation of FoxM1 in older mouse ? cells increases ?- cell proliferation and mass. RNA-sequencing revealed that FoxM1 over-expression in ? cells decreases expression of EP3 and increases expression of EP4, two G protein- coupled prostaglandin E2 (PGE2) receptors. In isolated islets from mouse and human, we found that pharmacological inhibition of EP3 or activation of EP4 promotes ?-cell proliferation and survival. The current proposal makes use of in vivo mouse models, human islet transplants and ex vivo islet cultures from humans with normoglycemia and Type 2 diabetes to determine the downstream signaling pathways that mediate the effects of inhibiting EP3 or activating EP4. Using phosphoprotein arrays of ex vivo treated mouse islets, we identified PLC? and PKA as acting downstream of EP3 inhibition or EP4 activation, respectively. In the current proposal we explore the hyopothesis that EP3 blockade (working through PLC?) or EP4 activation (working through PKA) will ameliorate diabetes and enhance human islet transplantation in vivo by increasing insulin secretion, and enhancing ?-cell proliferation and survival. We propose that FoxM1 directly activates EP4 while repressing EP3 expression. These studies are designed to identify molecular targets to enhance function, proliferation and survival of ? cells with the goal of increasing functional ? cell mass.
/Relevance Statement The incidence of Type 2 diabetes increases with age, in part due to a decreased ability of older ? cells to respond to proliferative cues. We discovered that the EP3 and EP4 prostaglandin E2 (PGE2) receptors reciprocally regulate ?-cell proliferation and survival, and that EP3 increases with age. This study makes use of in vivo mouse models as well as ex vivo studies in mouse and human islets to determine whether EP3 inhibition or EP4 activation can prevent or reverse diabetes by enhancing functional ?-cell mass and to identify the signaling pathways through which these PGE2 receptors mediate their effects in ? cells.
